Healx secures $47m to advance AI-driven rare disease treatments
Genetic Engineering & Biotechnology News (GEN) - 01-Aug-2024The UK-based company prepares for clinical trials with its innovative NF1 drug, HLX-1502
Join the club for FREE to access the whole archive and other member benefits.
Biotechnology company integrating artificial intelligence with expert pharmacology to discover treatments for rare diseases
Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.
Visit website: https://healx.io/
Details last updated 26-Sep-2019
The UK-based company prepares for clinical trials with its innovative NF1 drug, HLX-1502